TFS Capital’s Genocea Biosciences, Inc. GNCA Stock Holding History

TFS Capital’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-2,142	Closed	-$88K	–	979
2016 Q3	$88K	Sell	2,142 -1,927	-47%	-$75.6K	0.02%	669
2016 Q2	$133K	Buy	+4,069	New	+$149K	0.02%	825
2015 Q4	–	Sell	-3,488	Closed	-$191K	–	1019
2015 Q3	$191K	Sell	3,488 -1,922	-36%	-$191K	0.02%	746
2015 Q2	$594K	Buy	5,410 +3,466	+178%	+$322K	0.06%	471
2015 Q1	$184K	Buy	+1,944	New	+$137K	0.02%	795

Other funds holding GNCA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return

TFS Capital's GNCA Position: Q4 2016 in Review

TFS Capital sold out of Genocea Biosciences, Inc. (GNCA) in Q4 2016, closing a stake of 2,142 shares — an estimated $88K sold.

TFS Capital first reported a position in GNCA in Q1 2015 and held it in 5 quarters. The position peaked at $594K in Q2 2015. 47 funds tracked by Wall St. Rank hold GNCA as of Q4 2016.

TFS Capital reported no remaining Genocea Biosciences, Inc. position as of Q4 2016 after selling out during the quarter.
TFS Capital sold 2,142 Genocea Biosciences, Inc. shares in Q4 2016, an estimated $88K.
TFS Capital first reported a position in Genocea Biosciences, Inc. in Q1 2015 and held it in 5 quarters.
TFS Capital's Genocea Biosciences, Inc. position peaked at $594K in Q2 2015.
47 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q4 2016.

Based on TFS Capital's 13F filing for Q4 2016, filed 20 Jan 2017.